Javier G. Santos

Madrid, MD 28022, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Valence ratings of recorded media for adults with and without hearing loss.

Valence ratings of recorded media for adults with and without hearing loss.

Journal: International journal of audiology

Published: August 06, 2026

Valence ratings of recorded media for adults with and without hearing loss.

Valence ratings of recorded media for adults with and without hearing loss.

Journal: International journal of audiology

Published: August 06, 2026

Positional Vertigo in a Child with Hearing Loss.

Positional Vertigo in a Child with Hearing Loss.

Journal: Audiology research

Published: October 31, 2025

Chemotherapy and Other Systemic Drugs Used to Treat Gynecologic Carcinosarcomas (GCSs): A Retrospective Analysis from Hospital Clínico San Carlos (HCSC), An Academic Referral Centre for Rare Gynecological Malignancies in Madrid, Spain.

Chemotherapy and Other Systemic Drugs Used to Treat Gynecologic Carcinosarcomas (GCSs): A Retrospective Analysis from Hospital Clínico San Carlos (HCSC), An Academic Referral Centre for Rare Gynecological Malignancies in Madrid, Spain.

Journal: Cancers

Published: September 02, 2025

Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual disease.

Differential expression of cancer-related genes supports prediction of poor response to first-line treatments in T-ALL pediatric patients with high minimal residual disease.

Journal: Molecular oncology

Published: May 16, 2025

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.

Improved identification of T-ALL paediatric patients with low MRD but poor prognosis using a transcriptional signature.

Journal: British journal of haematology

Published: May 05, 2025

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.

Journal: NPJ precision oncology

Published: October 18, 2023

Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia.

Identification of NRF2 Activation as a Prognostic Biomarker in T-Cell Acute Lymphoblastic Leukaemia.

Journal: International journal of molecular sciences

Published: May 19, 2023

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.

The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib.

Journal: Molecular carcinogenesis

Published: April 11, 2023

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.

Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.

Journal: British journal of haematology

Published: March 19, 2023

SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.

SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.

Journal: British journal of haematology

Published: December 29, 2022

A Dual Role for FADD in Human Precursor T-Cell Neoplasms.

A Dual Role for FADD in Human Precursor T-Cell Neoplasms.

Journal: International journal of molecular sciences

Published: October 31, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026